篇名

從SARS到COVID-19看臺灣於藥品專利強授權之進程   免費試閱

並列篇名

The Development of Compulsory Licensing of Medicine from SARS to COVID-19 in Taiwan: An Expectation to the Legal State

作者
中文摘要

2019年底新冠肺炎疫情陸續於全球爆發,如何有效運用藥物治療並控制疫情,乃各國當務之急。有認為可借鏡2005年臺灣因禽流感,強制授權克流感藥品專利之經驗,以應目前防疫需求;惟本文認為,無專利強制授權即無法防疫之論調值得質疑,藥品強制授權存在著諸多可能的負面影響,在面對防疫需求的同時,亦應正視強制授權的最後手段性,以作出對臺灣整體最有利的判斷。新藥研發的時程長、風險高、投資大,強制授權之運用須符合最後手段性之要求,否則將影響新藥開發的募資動能與投入其研發的動機。

英文摘要

Since the corona virus has broken out in the end 2019 all around the world, it became the urgent priority to every countries to control it by taking medicine. It is said that the experience of the compulsory licensing of Tamiflu due to the avian influenza in 2005 in Taiwan could support it. Nevertheless, according to the opinion in this essay, it might be doubtful that preventing the epidemic couldn’t be possible without the compulsory licensing. There are lots of negative effects by compulsory licensing of medicine. At the meantime of preventing the epidemic, compulsory licensing as ultima ratio should be taken seriously, in order to make the suitable judgment for Taiwan. It takes time to discovery new drug, also risky and needs substantial investment. Compulsory licensing shall correspond to the demand as ultima ratio, otherwise it might influence the motivation to raise and invest funds to the discovery of new drugs.

起訖頁

064-078

出版單位
DOI

10.3966/241553062020060044006  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP